Atreca (BCEL) Stock Forecast, Price Target & Predictions
BCEL Stock Forecast
Atreca stock forecast is as follows: an average price target of $4.00 (represents a 4344.44% upside from BCEL’s last price of $0.09) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
BCEL Price Target
The average price target for Atreca (BCEL) is $4.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $4.00. This represents a potential 4344.44% upside from BCEL's last price of $0.09.
BCEL Analyst Ratings
According to 1 Wall Street analysts, Atreca's rating consensus is 'Buy'. The analyst rating breakdown for BCEL stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Atreca Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2022 | - | Wedbush | $4.00 | $1.48 | 171.19% | 4344.44% |
The latest Atreca stock forecast, released on Nov 15, 2022 by Wedbush company, set a price target of $4.00, which represents a 171.19% increase from the stock price at the time of the forecast ($1.48), and a 4344.44% increase from BCEL last price ($0.09).
Atreca Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.09 | $0.09 | $0.09 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Atreca stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Atreca's last price of $0.09. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 15, 2022 | Wedbush | Outperform | Outperform | Hold |
Atreca's last stock rating was published by Wedbush on Nov 15, 2022. The company gave BCEL a "Outperform" rating, the same as its previous rate.
Atreca Financial Forecast
Atreca Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $59.77K | $63.36K | $67.16K | $71.19K | $75.47K | $80.00K | $216.67K |
| High Forecast | $59.77K | $63.36K | $67.16K | $71.19K | $75.47K | $80.00K | $216.67K |
| Low Forecast | $59.77K | $63.36K | $67.16K | $71.19K | $75.47K | $80.00K | $216.67K |
| # Analysts | - | - | - | 1 | 1 | - | - |
| Surprise % | - | - | - | - | - | - | - |
Atreca's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BCEL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Atreca EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 1 | - | - |
| EBITDA | - | - | - | - | - | - | $-22.43M |
| Avg Forecast | $-35.86K | $-38.01K | $-40.30K | $-42.72K | $-45.28K | $-48.00K | $-130.00K |
| High Forecast | $-35.86K | $-38.01K | $-40.30K | $-42.72K | $-45.28K | $-48.00K | $-130.00K |
| Low Forecast | $-35.86K | $-38.01K | $-40.30K | $-42.72K | $-45.28K | $-48.00K | $-130.00K |
| Surprise % | - | - | - | - | - | - | 172.57% |
undefined analysts predict BCEL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Atreca's previous annual EBITDA (undefined) of $NaN.
Atreca Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 1 | - | - |
| Net Income | - | - | - | - | - | - | $-23.01M |
| Avg Forecast | $-9.44M | $-8.23M | $-8.62M | $-10.41M | $-13.77M | $-14.79M | $-25.46M |
| High Forecast | $-9.44M | $-8.23M | $-8.62M | $-10.41M | $-13.22M | $-14.79M | $-25.46M |
| Low Forecast | $-9.44M | $-8.23M | $-8.62M | $-10.41M | $-13.77M | $-14.79M | $-25.46M |
| Surprise % | - | - | - | - | - | - | 0.90% |
Atreca's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BCEL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Atreca SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 1 | - | - |
| SG&A | - | - | - | - | - | - | $6.64M |
| Avg Forecast | $1.29M | $1.36M | $1.45M | $1.53M | $1.62M | $1.72M | $4.66M |
| High Forecast | $1.29M | $1.36M | $1.45M | $1.53M | $1.62M | $1.72M | $4.66M |
| Low Forecast | $1.29M | $1.36M | $1.45M | $1.53M | $1.62M | $1.72M | $4.66M |
| Surprise % | - | - | - | - | - | - | 1.42% |
Atreca's average Quarter SG&A projection for Sep 23 is $1.72M, based on 0 Wall Street analysts, with a range of $1.72M to $1.72M. The forecast indicates a -74.07% fall compared to BCEL last annual SG&A of $6.64M (Dec 20).
Atreca EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 1 | - | - |
| EPS | - | - | - | - | - | - | $-0.62 |
| Avg Forecast | $-0.24 | $-0.21 | $-0.22 | $-0.26 | $-0.35 | $-0.38 | $-0.65 |
| High Forecast | $-0.24 | $-0.21 | $-0.22 | $-0.26 | $-0.34 | $-0.38 | $-0.65 |
| Low Forecast | $-0.24 | $-0.21 | $-0.22 | $-0.26 | $-0.35 | $-0.38 | $-0.65 |
| Surprise % | - | - | - | - | - | - | 0.97% |
According to undefined Wall Street analysts, Atreca's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BCEL previous annual EPS of $NaN (undefined).
Atreca Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
BCEL Forecast FAQ
Is Atreca a good buy?
Yes, according to 1 Wall Street analysts, Atreca (BCEL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of BCEL's total ratings.
What is BCEL's price target?
Atreca (BCEL) average price target is $4 with a range of $4 to $4, implying a 4344.44% from its last price of $0.09. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Atreca stock go up soon?
According to Wall Street analysts' prediction for BCEL stock, the company can go up by 4344.44% (from the last price of $0.09 to the average price target of $4), up by 4344.44% based on the highest stock price target, and up by 4344.44% based on the lowest stock price target.
Can Atreca stock reach $0?
BCEL's average twelve months analyst stock price target of $4 supports the claim that Atreca can reach $0 in the near future.
What are Atreca's analysts' financial forecasts?
Atreca's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $155.47K (high $155.47K, low $155.47K), average EBITDA is $-93.28K (high $-93.28K, low $-93.28K), average net income is $-28.56M (high $-28.009M, low $-28.56M), average SG&A $3.35M (high $3.35M, low $3.35M), and average EPS is $-0.726 (high $-0.712, low $-0.726). BCEL's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $261.48K (high $261.48K, low $261.48K), average EBITDA is $-157K (high $-157K, low $-157K), average net income is $-36.711M (high $-36.711M, low $-36.711M), average SG&A $5.63M (high $5.63M, low $5.63M), and average EPS is $-0.933 (high $-0.933, low $-0.933).